3C-DFM
Pharmaceutical compound
From Wikipedia, the free encyclopedia
3C-DFM, also known as 4-(2,2-difluoromethoxy)-3,5-dimethoxyamphetamine or as or as α-methyldifluoromescaline (3C-difluoromescaline), is a serotonin receptor modulator of the phenethylamine and 3C families.[1][2][3] It is the amphetamine (α-methyl) derivative of the psychedelic drug difluoromescaline (DFM).[1][2][3] The properties and effects of 3C-DFM in humans are unknown.[1][2] The drug shows affinity for the serotonin 5-HT2 receptors and is known to act as an agonist of the serotonin 5-HT2A and 5-HT2B receptors.[3][2] 3C-DFM was first described in the scientific literature by Daniel Trachsel by 2012.[2][1][3] It is a controlled substance in Ukraine.[4] The drug is also a controlled substance in Canada under phenethylamine blanket-ban language.[5]
- None
| Clinical data | |
|---|---|
| Other names | 3C-Difluoromescaline; α-Methyldifluoromescaline; 4-(2,2-Difluoromethoxy)-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-(2,2-difluoromethoxy)amphetamine; 4-Difluoromethoxy-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-difluoromethoxyamphetamine |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C12H17F2NO3 |
| Molar mass | 261.269 g·mol−1 |
| 3D model (JSmol) | |
| |
| |